<DOC>
<DOCNO>EP-0654036</DOCNO> 
<TEXT>
<INVENTION-TITLE>
LIPONUCLEOTIDES OF SECO-NUCLEOSIDES, THEIR PREPARATION AND THEIR USE AS ANTI-VIRAL DRUGS
</INVENTION-TITLE>
<CLASSIFICATIONS>C04B2800	C04B2816	A61K31675	C07F96561	A61P3112	A61P3100	A61K31675	A61P3122	C07F900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C04B	C04B	A61K	C07F	A61P	A61P	A61K	A61P	C07F	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C04B28	C04B28	A61K31	C07F9	A61P31	A61P31	A61K31	A61P31	C07F9	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention concerns phospholipid derivatives of seco-nucleosides, in which a lipid with a substituted three-carbon-atom basic structure is linked to a seco-nucleoside via a phosphate or thiophosphate group. The invention also concerns the use of such derivatives as anti-viral drugs.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
BOEHRINGER MANNHEIM GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
BOEHRINGER MANNHEIM GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HERRMANN DIETER
</INVENTOR-NAME>
<INVENTOR-NAME>
ZILCH HARALD
</INVENTOR-NAME>
<INVENTOR-NAME>
HERRMANN, DIETER
</INVENTOR-NAME>
<INVENTOR-NAME>
ZILCH, HARALD
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Liponucleotides of formula I 

 
in which 


R
1
denotes a straight-chained or branched, 
saturated or unsaturated alkyl chain with 

1-20 carbon atoms which can be substituted if 
desired once or several times by phenyl, 

halogen, C
1
-C
6
 alkoxy, C
1
-C
6
 alkylmercapto, 
C
1
-C
6
 alkoxycarbonyl, C
1
-C
6
 alkylsulfinyl or 
C
1
-C
6
 alkylsulfonyl groups, 
R
2
denotes a straight-chained or branched, 
saturated or unsaturated alkyl chain with 

1-20 carbon atoms which can be substituted if 
desired once or several times by phenyl, 

halogen, C
1
-C
6
 alkoxy, C
1
-C
6
 alkylmercapto, 
C
1
-C
6
 alkoxycarbonyl, C
1
-C
6
 alkylsulfinyl or 
C
1
-C
6
 alkylsulfonyl groups,  
 
R
3
denotes hydrogen or a C
1
-C
6
 alkyl group which is 
substituted if desired by hydroxy, 
R
4
can be hydrogen, hydroxy, amino or an amino 
group substituted once or twice by C
1
-C
6
 alkyl, 
R
5
can be hydrogen, hydroxy, amino or an amino 
group substituted once or twice by C
1
-C
6
 alkyl, 
X
represents a valency dash, oxygen, sulphur, 
sulfinyl or sulfonyl, 
Y
has the same meaning as X and the two groups X 
and Y can be the same or different, 
Z
can be oxygen or sulphur, 
 
their tautomers and their physiologically tolerated 

salts of inorganic and organic acids and bases. 
Liponucleotides as claimed in claim 1, wherein R
1
 
denotes a straight-chained C
9
-C
14
 alkyl group which 
can be substituted by a C
1
-C
6
 alkoxy or a C
1
-C
6
 
alkylmercapto group. 
Liponucleotides as claimed in claim 2, wherein 
R
1
 denotes a decyl, undecyl, dodecyl, tridecyl or 
tetradecyl group which can be substituted by a 

methoxy, ethoxy, butoxy, hexyloxy, methylmercapto, 
ethylmercapto, propylmercapto, butylmercapto or 

hexylmercapto group.  
 
Liponucleotides as claimed in one of the claims 1-3, 
wherein R
2
 denotes a straight-chained C
9
-C
14
 
alkyl group which can be substituted by a C
1
-C
6
 
alkoxy or C
1
-C
6
 alkylmercapto group. 
Liponucleotides as claimed in claim 4, wherein R
2
 
denotes a decyl, undecyl, dodecyl, tridecyl or 

tetradecyl group which can be substituted by a 
methoxy, ethoxy, propoxy, butoxy, hexyloxy, 

methylmercapto, ethylmercapto, butylmercapto or 
hexylmercapto group. 
Liponucleotides as claimed in one of the claims 
1-5, wherein R
3
 denotes hydrogen or hydroxy C
1
-C
6
 
alkyl. 
Liponucleotides as claimed in one of the claims 
1-6, wherein R
4
 denotes hydroxy or amino. 
Liponucleotides as claimed in one of the claims 
1-7, wherein R
5
 denotes hydrogen or amino. 
Process for the production of liponucleotides of 
formula I as claimed in one of the claims 1-8, 

wherein  
 


a) a compound of formula II, 

 
in which R
1
, R
2
, X, Y and Z have the stated, 
meanings is reacted in an inert solvent with a 

compound of the general formula III, 

 
in which R
3
, R
4
 and R
5
 have the above-mentioned 
meaning, using a condensing agent and after 

completion of hydrolysis the oxygen protecting 
groups which may be present are cleaved off if 

desired according to conventional methods in 
nucleoside chemistry or  

 
b. a compound of formula IV 

 
in which R
1
, R
2
, X, Y and Z have the above-mentioned 
meanings is reacted with a compound of 

formula III, in which R
3
, R
4
 and R
5
 have the stated 
meanings, in the presence of phospholipase D in an 

inert solvent in the presence of a suitable buffer 
and after the reaction is completed the oxygen 

protecting group which may be present is cleaved 
off if desired according to conventional methods in 

nucleoside chemistry, and
 
subsequently compounds of formula I are converted 

into their physiologically tolerated salts if 
desired. 
Pharmaceutical agent containing at least one 
liponucleotide of formula I as claimed in one of 

the claims 1-8 as well as further conventional 
pharmaceutical auxiliary or carrier substances.  

 
Use of liponucleotides of formula I as claimed in 
one of the claims 1-8 for the production of 

pharmaceutical agents for the treatment of viral or 
retroviral infections. 
</CLAIMS>
</TEXT>
</DOC>
